Reported about 1 month ago
Eli Lilly has seen a remarkable 58% increase in its stock price in 2024, driven by strong performance in diabetes and obesity care, as well as the recent FDA approval of its eczema treatment, Ebglyss. The company is positioned to tap into a $31 billion market opportunity for eczema treatment and is expanding its portfolio in Alzheimer's care. While its P/E ratio is high at 113, the multiple growth opportunities make Lilly stock an attractive option for long-term investors.
Source: YAHOO